(b)(4).Date sent to the fda: 1/23/2020.Additional information: d10, h6.Additional h3 investigation summary: only pictures were returned for analysis.Upon visual inspection of the pictures, an open sample including a stratafix spiral suture, along with a winding former, paper lid and the foil primary package from a startafix symmetric can be observed.In addition, a retained sample was opened and no mixed product was observed.It should be noted that stratafix spiral suture product seen in the pictures corresponds to product that is manufactured at the san lorenzo puerto rico site, whereas the packaging components within the picture correspond to stratafix symmetric product that is manufactured in the juarez mexico site.As the suture and packaging material are not available at the same site, no conclusion could be reach on what could have caused the reported event.The manufacturing records were reviewed, and the manufacturing/packaging criteria were met prior to the release of this batch.Additional h3 investigation summary: an empty opened foil and an open labeled winding former with a re-winding needle/suture combination of product code sxpp1a405, lot # pdz994 were received for evaluation.During the visual inspection of the sample, the strand belongs to stratafix spiral suture and the paper lid and the foil package from a startafix symmetric.In addition, a retained sample was opened, and no mixed product was observed.It should be noted that stratafix spiral suture product is manufactured at the san lorenzo puerto rico site, and the packaging components correspond to stratafix symmetric product that is manufactured in the juarez mexico site.Therefore, the product could not be mixed our manufacturing process.The manufacturing records were reviewed, and the manufacturing/packaging criteria were met prior to the release of this batch.
|